FORWARD PHARMA A/S-ADR (FWP) Stock Price & Overview
NASDAQ:FWP • US34986J2042
Current stock price
The current stock price of FWP is 1.95 USD. Today FWP is up by 7.73%. In the past month the price decreased by -35%. In the past year, price decreased by -67.34%.
FWP Key Statistics
- Market Cap
- 191.616M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.02
- Dividend Yield
- N/A
FWP Stock Performance
FWP Stock Chart
FWP Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to FWP. When comparing the yearly performance of all stocks, FWP is a bad performer in the overall market: 91.28% of all stocks are doing better.
FWP Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to FWP. No worries on liquidiy or solvency for FWP as it has an excellent financial health rating, but there are worries on the profitability.
FWP Earnings
FWP Forecast & Estimates
FWP Groups
Sector & Classification
FWP Financial Highlights
Over the last trailing twelve months FWP reported a non-GAAP Earnings per Share(EPS) of -0.02. The EPS increased by 71.1% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
FWP Ownership
FWP Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.56 | 362.808B | ||
| AMGN | AMGEN INC | 15.07 | 186.117B | ||
| GILD | GILEAD SCIENCES INC | 14.87 | 165.442B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.44 | 111.051B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.9 | 79.011B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.27 | 41.154B | ||
| INSM | INSMED INC | N/A | 30.431B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 29.508B | ||
| NTRA | NATERA INC | N/A | 29.114B | ||
| BIIB | BIOGEN INC | 11.82 | 27.29B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.8 | 25.135B | ||
| MRNA | MODERNA INC | N/A | 21.507B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.454B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About FWP
Company Profile
Forward Pharma A/S is a biopharmaceutical company, which engages in the research and development of medicinal treatment for inflammatory and neurological indications. The firm granted to Biogen an irrevocable license to all of its IP through the License Agreement and received from Biogen a non-refundable cash fee of $1.25 billion in February 2017, with the return of EUR 917.7 million to shareholders through a capital reduction in September 2017. The firm has the opportunity to receive royalties from Biogen on Biogen’s net sales of Tecfidera or other DMF products for multiple sclerosis outside the U.S., dependent on, among other things, a favorable outcome in Europe with respect to the 355 Patent Opposition Proceeding, including any appeal thereto.
Company Info
IPO: 2014-10-15
FORWARD PHARMA A/S-ADR
Oestergade 24A, 1, Copenhagen K
COPENHAGEN 1100 DK
CEO: Claus Bo Svendsen
Employees: 4
Phone: 4533444242.0
FORWARD PHARMA A/S-ADR / FWP FAQ
Can you describe the business of FORWARD PHARMA A/S-ADR?
Forward Pharma A/S is a biopharmaceutical company, which engages in the research and development of medicinal treatment for inflammatory and neurological indications. The firm granted to Biogen an irrevocable license to all of its IP through the License Agreement and received from Biogen a non-refundable cash fee of $1.25 billion in February 2017, with the return of EUR 917.7 million to shareholders through a capital reduction in September 2017. The firm has the opportunity to receive royalties from Biogen on Biogen’s net sales of Tecfidera or other DMF products for multiple sclerosis outside the U.S., dependent on, among other things, a favorable outcome in Europe with respect to the 355 Patent Opposition Proceeding, including any appeal thereto.
Can you provide the latest stock price for FORWARD PHARMA A/S-ADR?
The current stock price of FWP is 1.95 USD. The price increased by 7.73% in the last trading session.
Does FORWARD PHARMA A/S-ADR pay dividends?
FWP does not pay a dividend.
What is the ChartMill technical and fundamental rating of FWP stock?
FWP has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
On which exchange is FWP stock listed?
FWP stock is listed on the Nasdaq exchange.
Can you provide the sector and industry classification for FORWARD PHARMA A/S-ADR?
FORWARD PHARMA A/S-ADR (FWP) operates in the Health Care sector and the Biotechnology industry.
Would investing in FORWARD PHARMA A/S-ADR be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on FWP.